Os copio el último boletín de Myeloma Minute(IMF)
"WHAT'S NEWSThe IMF is going to the IMW!
For those of you who get itchy when presented with more acronyms than usual (we know how many there are in myeloma, and try to help whenever we can), the IMW is the International Myeloma Workshop, a biannual meeting of myeloma experts from all over the world. Presentations given there highlight emerging advances in the understanding of the biology and treatment of myeloma. This year the participants are meeting in Paris at the Louvre! The meeting will run from May 03- 06, 2011. The IMF will be there to bring you daily video session summaries. After the meeting, webcasts of every presentation will be available on our website. So, stay tuned!
http://www.myeloma-paris2011.com/
NCCN Tweaks 2011 Multiple Myeloma Guidelines
The latest version of the National Comprehensive Cancer Network (NCCN) multiple myeloma guidelines include a few small changes to reflect recent advances in diagnosis and treatment that were presented at the NCCN 16th Annual Conference. The tweaks include moving the serum free light chain assay from "useful under some circumstances" to a recommended part of the initial diagnostic workup, as well as adding fluorescence in situ hybridization (FISH) for 1q21 amplification. [The link above is to a PDF of the Patient Guidelines. To see the Physician Guidelines, you must register and login here. The registration and login is free] (from Medscape and the NCCN)
http://www.nccn.com/images/patient-guid ... yeloma.pdf
Don't miss the Myeloma Awareness Month Teleconferences!
In the third teleconference of Myeloma Awareness Month 2011, Stephanie Turnbull of Diplomat Specialty Pharmacy, discussed the ins and outs of Medicare. If you have missed any of the teleconferences, you can access them on the IMF website.
http://myeloma.org/IndexPage.action?tab ... tegoryId=0
Researchers sequence multiple myeloma genome in landmark Nature study
Using new genome sequencing technologies, researchers from the John Theurer Cancer Center at Hackensack University Medical Center joined colleagues from 20 major North American research institutions to publish the first complete genomic portrait of multiple myeloma, a highly aggressive blood cancer. Findings from the study point to new directions for potential myeloma therapies, and begin to unlock the mysteries of what causes this devastating malignancy. (from e! Science News)
http://esciencenews.com/articles/2011/0 ... ture.study
Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
A recent study found that Kyphon Balloon Kyphoplasty provided cancer patients better back-specific function, more rapid back pain relief and improved quality of life compared with non-surgical care one month after treatment. (from the Vancouver Sun)
Read Medtronic's press release.
http://www.vancouversun.com/business/Ky ... z1HMnlWV42
Onyx Gets Fast-Track Status From FDA For Carfilzomib
The U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma. The Fast Track designation process was developed by the FDA to facilitate the development, and expedite the review of drugs to treat serious or life-threatening diseases and address unmet medical needs. (from the Wall Street Journal)
Read Onyx's press release.
http://online.wsj.com/article/BT-CO-201 ... 17296.html
1000 CRANES OF HOPE
Millennium: The Takeda Oncology Company has chosen to artistically represent their commitment to patients through the creation and construction of a monument at their headquarters in Cambridge, MA. This exhibit contains one thousand origami-folded cranes—each crafted from the handwritten personal wishes of cancer patients, employees, physicians, caregivers and advocates. Now you have the opportunity to create a Crane of Hope online, and for every Crane created during the months of March, April and May, Millennium will make a donation to the IMF.
http://myeloma.org/ArticlePage.action?t ... 63&aTab=-1
Progression From Precursor Disease to Multiple Myeloma
Thomas E. Finucane, MD, of the Department of Medicine at Johns Hopkins Bayview Medical Center in Baltimore, writes to the editor of the Journal of the American Medical Associaton about a recent review of multiple myeloma precursor disease. Read the reply (from the Journal of American Medical Association)
http://jama.ama-assn.org/content/305/11/1094.3.full
Thalidomide's Comeback. Who'd have thought the drug would have a second life?
The most reviled drug of the 20th century is, incredibly, on its way to a second act. Thalidomide, used in the late 1950s and early 1960s as a sedative and anti-nausea medication, became the ultimate symbol of pharmacopoeia gone awry. Recently, thalidomide has slouched back toward respectability as an FDA approved treatment for patients with newly diagnosed multiple myeloma. (from Slate)
http://www.slate.com/id/2280406/
IMF Research Grant Awards Presented at ASH
The Brian D. Novis and Aki Horinouchi Research Grants were presented during the American Society of Hematology (ASH) meeting in Orlando, Florida. Two senior grants, three junior grants, and, for the first time, two Aki Horinouchi grants were awarded to the researchers.
http://myeloma.org/IndexPage.action?tab ... goryId=551
Development of resveratrol drug, SRT501, terminated
GlaxoSmithKline is dumping its program for SRT501, a special formulation of resveratrol which the pharma company scooped up in the $720 million buyout of Sirtris in 2008. (from Fierce Biotech)
http://www.fiercebiotech.com/story/weak ... 2010-12-01
FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma
Senesco Technologies, Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation for the company's lead drug candidate SNS01-T for treatment of multiple myeloma. (from The Medical News)
http://www.news-medical.net/news/201101 ... eloma.aspx
Thinking about starting a support group? The IMF Support Group Team is here to help!
Through a network of over 100 myeloma support groups, the IMF seeks to ensure that patients and families have local access to support and information. Among their many benefits, support groups can increase knowledge, decrease anxiety and create a sense of community. The IMF can offer you tips to get started and logistics to consider when starting up a myeloma specific support group.
http://myeloma.org/pdfs/SupportGroupTeamFlyer.pdf
Charitable IRA Rollover Extended for 2010 and 2011
Just a reminder that among the multitude of items included in the Tax Relief Act, signed into law by President Obama on December 17th, was an extension of the Charitable IRA Rollover provision through the end of 2011.
http://myeloma.org/ArticlePage.action?t ... 83&aTab=-1
We invite you to visit and participate in the International Myeloma Foundation's newly-launched blogs.
We have expanded our website to include blogs by patients, caregivers, nurses, doctors and others to provide a forum for discussion with the community on matters of importance to everyone battling myeloma. You can also now comment on any article on our site by using the comment tab. Come visit our corner of the blogosphere!
http://myeloma.org/ArticlePage.action?t ... 91&aTab=-1
WHAT'S NEW IN RESEARCHMembers of Scientific Advisory Board*, Members of International Myeloma Working Group†
* Toward deeper response in MM
Joan Blade*† and Carlos Fernandez de Larrea
Blood 2011;117 2986-2987
http://bloodjournal.hematologylibrary.o ... /2986.full
* Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
Francesca Gay, Alessandra Larocca, Pierre Wijermans, Federica Cavallo, Davide Rossi, Ron Schaafsma, Mariella Genuardi, Alessandra Romano, Anna Marina Liberati, Agostina Siniscalchi, Maria T. Petrucci, Chiara Nozzoli, Francesca Patriarca, Massimo Offidani, Roberto Ria, Paola Omede, Benedetto Bruno, Roberto Passera, Pellegrino Musto, Mario Boccadoro*†, Pieter Sonneveld*†, and Antonio Palumbo*†
Blood 2011;117 3025-3031
http://bloodjournal.hematologylibrary.o ... 5.abstract
* Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
Philippe Moreau*†, Michel Attal*†, Brigitte Pegourie, Lucie Planche, Cyrille Hulin, Thierry Facon, Anne-Marie Stoppa, Jean-Gabriel Fuzibet, Bernard Grosbois, Chantal Doyen, Nicolas Ketterer, Catherine Sebban, Brigitte Kolb, Carine Chaleteix, Mamoun Dib, Laurent Voillat, Jean Fontan, Laurent Garderet, Jerome Jaubert, Claire Mathiot, Dixie Esseltine, Herve Avet-Loiseau, Jean-Luc Harousseau*, and for the IFM 2005-01 study investigators*
Blood 2011;117 3041-3044
http://bloodjournal.hematologylibrary.o ... 1.abstract
* Erythropoietin couples erythropoiesis, B lymphopoiesis, and bone homeostasis within the bone marrow microenvironment
Sofie Singbrant, Megan R. Russell, Tanja Jovic, Brian Liddicoat, David J. Izon, Louise E. Purton, Natalie A. Sims, T. John Martin, Vijay G. Sankaran, and Carl R. Walkley
Blood published 18 March 2011, 10.1182/blood-2010-11-320564
http://bloodjournal.hematologylibrary.o ... 4.abstract
* IMiD(R) immunomodulatory compounds block C/EBP{beta} translation through eIF4E downregulation resulting in inhibition of MM
Shirong Li, Rekha Pal, Sara A. Monaghan, Peter Schafer, Hongjiao Ouyang, Markus Mapara, Deborah L. Galson, and Suzanne Lentzsch†
Blood published 9 March 2011, 10.1182/blood-2010-10-314278
http://bloodjournal.hematologylibrary.o ... 8.abstract
CLINICAL TRIALSCARFILZOMIB trials
http://www.clinicaltrials.gov/ct2/resul ... &recr=Open
REVLIMID® trials
http://www.clinicaltrials.gov/ct2/resul ... &recr=Open
THALOMID® trials
http://www.clinicaltrials.gov/ct2/resul ... &recr=Open
VELCADE® trial
http://www.clinicaltrials.gov/ct2/resul ... &recr=Open
VORINOSTAT
http://myeloma.org/IndexPage.action?tab ... goryId=438
A Phase II Study of AZD6244 in Multiple Myeloma patients with relapsed/refractory disease who have had two or more prior therapies
The purpose of this study is to find out what effects, good and/or bad, AZD6244 has on participants and their multiple myeloma. In some types of cancer such as myeloma, a protein called MEK is overactive.
http://clinicaltrials.gov/ct2/show/NCT01085214
Natural History of MGUS and Smoldering Myeloma
The purpose of this study is to discover risk factors that may cause MGUS and SMM to progress to multiple myeloma. Individuals need to be at least 18 years of age who have been diagnosed with either MGUS or SMM but do not have multiple myeloma.
http://clinicaltrials.gov/ct2/show/NCT01109407
ASPIRE: Phase III study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) vs lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma
The purpose of this study is to compare progression-free survival in subjects with relapsed multiple myeloma who are receiving CRd vs subjects receiving Rd in a randomized multicenter setting.
http://myeloma.org/IndexPage.action?tab ... goryId=438
Para traducir los articulos, os aconsejo este link:http://translate.google.es/#
Un abrazo
